An Open-label, Single Dose, Randomised, Crossover Trial in Healthy Male Subjects to Investigate the Relative Bioavailability of Tablet and Oral Solution of Two Doses of BI 144807 and Relative Bioavailability of BI 144807 When Administered as Tablet Under Fed and Fasted Conditions
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2013
Price : $35 *
At a glance
- Drugs BI 144807 (Primary)
- Indications Allergic rhinitis; Asthma
- Focus Pharmacokinetics
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jul 2013 New trial record